Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $27.14

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $27.1429.

A number of equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Maxim Group increased their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, BTIG Research dropped their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th.

Zevra Therapeutics Stock Down 1.9%

Shares of ZVRA stock opened at $11.61 on Friday. Zevra Therapeutics has a 12-month low of $7.51 and a 12-month high of $15.03. The firm has a fifty day moving average of $11.64 and a 200-day moving average of $11.21. The firm has a market capitalization of $689.40 million, a price-to-earnings ratio of 12.62 and a beta of 0.95.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. Research analysts expect that Zevra Therapeutics will post 0.72 earnings per share for the current year.

Insider Activity

In other news, Director Corey Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director owned 1,800 shares of the company’s stock, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC acquired a new stake in shares of Zevra Therapeutics in the 1st quarter valued at about $11,184,000. Dimensional Fund Advisors LP lifted its holdings in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Zevra Therapeutics during the second quarter worth about $2,846,000. Finally, Globeflex Capital L P bought a new position in shares of Zevra Therapeutics during the second quarter worth about $2,752,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a rare-disease biopharmaceutical company focused on developing and commercializing treatments for conditions with significant unmet medical needs. The company combines data science, patient-focused drug development and traditional pharmaceutical research to advance therapies for rare metabolic and neurological disorders.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children at least 2 years old, in combination with miglustat.